Recipharm and Oncopeptides: Successful Collaboration in the Development of Melflufen, a Peptidase-Potentiated Alkylating Agent in Clinical Trials

Despite recent advances in therapy, multiple myeloma (MM) remains incurable, showing the need for novel therapies.

Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly cytotoxic payload into myeloma cells through peptidase activity. Melflufen is currently being evaluated for the treatment of multiple myeloma in a phase III study.

/sites/default/files/media/Poster_Recipharm%20and%20Oncopeptides%20Successful%20Collaboration%20in%20the%20Development%20of%20Melflufen%20a%20Peptidase-Potentiated%20Alkylating%20Agent%20in%20Clinical%20Trials.pdf
False
True